Latest Intelligence on Pharmaceuticals and Healthcare in Switzerland

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Genentech/Roche: significant potential for Avastin in glioma

Clinical phase II trial data has shown a combination of Genentech/Roche's Avastin and Pfizer's Camptosar to confer antitumor activity in the treatment of glioma. Although Avastin has already reached blockbuster status in other indications, the severe unmet needs and lack of alternative treatment options in this patient population mean that, if approved, eventual uptake is likely to be promising.

Published By Datamonitor
19 Feb 2007
CommentWire
CommentWire

Genentech/Roche: Avastin suffers a minor setback

Roche has announced that a Phase III trial for Avastin in early-stage colorectal cancer has failed to meet its primary endpoint. Although this setback is unlikely to affect Avastin's sales in its approved indications, it creates a commercially attractive opportunity for rival drug Erbitux to gain first-to-market status in early-stage colorectal cancer.

Published By Datamonitor
22 Apr 2009
CommentWire
CommentWire

Genentech/Roche: another indication for the blockbuster Avastin?

Clinical trial data has shown a significant increases in progression-free survival when Avastin is added to standard interferon treatment for first-line metastatic renal cell carcinoma. Although Avastin has already reached blockbuster status, it will need to demonstrate significant clinical benefit in its final results in order to compete with its cheaper, small molecule competitors.

Published By Datamonitor
12 Dec 2006
CommentWire
CommentWire

Ferring: strong R&D base for next generation incontinence treatment

Ferring's next generation of antidiuretics to treat urinary incontinence could make use of pioneering research by Nobel Laureate Professor Agre. The company's close relationship with academia and its own long history of research in the urinary incontinence field should strengthen its position as a leading urology player.

Published By Datamonitor
01 Mar 2004
CommentWire
CommentWire

Eczema therapies: Fujisawa gets help as Novartis gains ground

The success of Novartis' [NVS] eczema cream in its first year of sales has caused Fujisawa [FJSPF.PK] to strengthen marketing arrangements for its own eczema drug in the key US market. Fujisawa's initial attempt to go it alone in the US has resulted in slow sales, but the struggle between Novartis and its Japanese rival is only just beginning.

Published By Datamonitor
14 Jul 2003
CommentWire
CommentWire

DuPont: the bidding war

Published By Datamonitor
07 Jun 2001
CommentWire
CommentWire

Debiopharm: a bleak future for Trelstar

Published By Datamonitor
09 Jul 2001
CommentWire
CommentWire

Chugai/Roche: the best of both worlds

Chugai and Roche's merger has come at an important time for the Japanese pharmaceutical industry. As regulatory changes make it easier for western drugs and drug-makers to enter, Japanese pharma companies are facing fewer opportunities to benefit from in-licensing. As a result, innovation is becoming vitally important for domestic growth.

Published By Datamonitor
03 Oct 2002
CommentWire
CommentWire

Biogen: Amevive decision eases Avonex woes

Biogen's Amevive has moved a step closer to the market, as an FDA panel urged its approval for treating adult chronic psoriasis. If the drug is approved, it will be a welcome diversification for Biogen. Its only marketed product, MS drug Avonex, is under serious threat from the FDA's recent decision to approve Serono's Rebif in the US.

Published By Datamonitor
29 May 2002
CommentWire
CommentWire

Biogen/Serono: pistols at dawn

Published By Datamonitor
29 Jun 2001

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | » »|

No help is available.